APA (7th ed.) Citation

Khalafallah, A. A., Slancar, M., Cosolo, W., Abdi, E., Chern, B., Woodfield, R. J., & Copeman, M. C. (2018). Long‐term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. European Journal of Cancer Care, 27(2), 1. https://doi.org/10.1111/ecc.12638

Chicago Style (17th ed.) Citation

Khalafallah, A. A., M. Slancar, W. Cosolo, E. Abdi, B. Chern, R. J. Woodfield, and M. C. Copeman. "Long‐term Safety of Monthly Zoledronic Acid Therapy Beyond 1 year in Patients with Advanced Cancer Involving Bone (LoTESS): A Multicentre Prospective Phase 4 Study." European Journal of Cancer Care 27, no. 2 (2018): 1. https://doi.org/10.1111/ecc.12638.

MLA (9th ed.) Citation

Khalafallah, A. A., et al. "Long‐term Safety of Monthly Zoledronic Acid Therapy Beyond 1 year in Patients with Advanced Cancer Involving Bone (LoTESS): A Multicentre Prospective Phase 4 Study." European Journal of Cancer Care, vol. 27, no. 2, 2018, p. 1, https://doi.org/10.1111/ecc.12638.